



Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

PROCTER & GAMBLE LICENSES METACORE AND METABASE FROM GENEGO

St. Joseph, Michigan, May 9th, 2005 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Procter & Gamble Pharmaceuticals, Inc., a subsidiary of The Procter & Gamble Company (NYSE – PG), has licensed MetaCore and MetaBase from GeneGo. MetaCore™ is a manually curated, proprietary human database with the ability to work with rat, mouse, fly, yeast and worm orthologs. MetaCore also includes a suite of software tools for analysis in the context of pathways. MetaBase provides researchers with direct access to MetaCore content and the ability to add their own algorithms and data to the MetaCore schema.

GeneGo's MetaCore platform has unique interoperability by allowing users to examine multiple types of data concurrently such as gene expression, proteomics and metabolomics in the context of biological networks and pathways. MetaCore also allows users to edit pathways, add their own knowledge and annotations. MetaBase is an open-architecture, manually curated content database with information on mammalian signaling, metabolism, transcription factors, receptors, drug targets and bioactive chemistry.

“We are glad to see Procter & Gamble choosing our products to support their R&D efforts”, said Julie Bryant, VP Business development of GeneGo. “We are pleased that a company of the caliber of P&G recognizes the potential value that our manually curated databases and analytical tools can add to their already strong R&D programs.”

About GeneGo

GeneGo is a Michigan-based company developing systems biology technology for life science research. The original computational platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolites, phenotypic data etc.) and relevant active chemistry (metabolites, drugs, other xenobiotics) within the framework of biological pathways and networks. GeneGo's flagship product, MetaCore™, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug™ is designed for prediction of human metabolism and toxicity for novel small molecules compounds.

MetaBase™ represents the knowledge base for MetaCore™. For more information, please visit the company's web site at www.genego.com.

MetaCore™ and MetaDrug™ are trademarks of GeneGo, Inc.